CBD: FDA Impact & the Path Forward

Federal regulation of CBD issued by the FDA has been anticipated since 2020. With no new updates in sight, we've forecasted US CBD market growth scenarios with and without federal regulation.

Join our Senor Director of Insights, Meg Bluth, and Senior Insights Analyst Matt Zehner as they discuss Brightfield Group's CBD 2022 Mid-Year report, CBD: FDA Impact & the Path Forward.
 
You'll learn:

+ How federal guidance could drive a 40%+ CAGR in key retail channels

+ How the top 20 CBD companies performed this quarter

+ The key growth drivers affecting the CBD industry

+ How companies have moved to define CBD’s place in the wider wellness market

+ Which industry leaders are growing the fastest?

+ And much more!